Pelago Bioscience began with a method invented at Karolinska Institutet. Its growth into a drug discovery partner spanning biology and chemistry suggests that a founder’s work is not only to prove the science, but to keep finding the expertise that carries it further.

After two decades as the idea that never quite worked, the personalised cancer vaccine has cut melanoma recurrence by 49 per cent in Phase 3. Researchers, a founder and an investor unpack what changed, what it will cost and which tumours come next. Read the full article.

Why has the fixed-dose pill survived for nearly two centuries? In the first episode of Capital Insights, our new podcast, OnDosis CEO Martin Olovsson explains how precision dosing could become pharma's biggest untapped opportunity, and what it takes to cross the Atlantic. Read the article, and listen Capital Insights on Spotify.

Insights Accelerated was among just 200 accredited press outlets at this year’s BIO, where capital felt scarcer, more selective, and more global — and investors’ questions moved earlier in the development timeline. Here is a pulse check from San Diego, across five companies working the gap between promise and proof.

Why did fewer meetings at BIO 2026 deliver more than a packed calendar ever did? In a recent interview AOP Health's Eszter Kormann shares her "crown jewel" philosophy of sourcing — why fair beats cheap, what happens after the signature, and why the scarcest resource in dealmaking is conviction.

AnaCardio is using its CEO’s experience on both sides of pharma partnering to shape a global Phase 2b for AC01, its oral treatment candidate for heart failure.

In a recent interview, Helena shared her perspective on why authenticity, a tolerance for friction, and the ability to "read the room" from a macro perspective are the tools to thrive in negotiations. 

Insights Accelerated was among just 200 accredited press outlets at this year’s BIO, where capital felt scarcer, more selective, and more global — and investors’ questions moved earlier in the development timeline. Here is a pulse check from San Diego, across five companies working the gap between promise and proof.

Many Nordic life science companies have world-class science, yet struggle to attract the attention they deserve. In this exclusive Venture Road UK conversation, investor Altar Munis reveals what truly matters to UK investors—and why the right story can be just as important as the science itself.

Discover how leading players from the UK and Nordic life sciences ecosystems are joining forces to accelerate innovation and advance the future of Precision Health.